Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL

Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure–response relationships of obinutuzumab still n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CPT Pharmacometrics Syst Pharmacol
Autors principals: Gibiansky, E, Gibiansky, L, Carlile, D J, Jamois, C, Buchheit, V, Frey, N
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4474170/
https://ncbi.nlm.nih.gov/pubmed/25353187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2014.42
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars